Journal
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
Volume 30, Issue -, Pages -Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S2045796021000573
Keywords
Comorbidity; impairment; major depressive disorder; suicidal thoughts and behaviours
Categories
Funding
- United States National Institute of Mental Health (NIMH) [R01 MH070884]
- John D. and Catherine T. MacArthur Foundation
- Pfizer Foundation
- United States Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
- Fogarty International Center [FIRCA R03-TW006481]
- Pan American Health Organization
- Eli Lilly and Company
- Ortho-McNeil Pharmaceutical Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb
- Australian Government Department of Health and Ageing
- Argentinian Ministry of Health (Ministerio de Salud de la Nacion) [2002-17270/13-5]
- State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant [03/00204-3]
- Ministry of Health
- National Center for Public Health Protection
- Ministry of Social Protection
- Center for Excellence on Research in Mental Health (CES University)
- Secretary of Health of Medellin
- European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
- Piedmont Region (Italy)
- Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
- Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
- Generalitat de Catalunya [2017 SGR 452, 2014 SGR 748]
- Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
- Iraqi IMHS team
- Japanese Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
- European Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
- Israel National Institute for Health Policy and Health Services Research
- National Insurance Institute of Israel
- Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006]
- Lebanese Ministry of Public Health
- WHO (Lebanon)
- National Institute of Health/Fogarty International Center [R03 TW006481-01]
- Algorithm
- AstraZeneca
- Benta
- Bella Pharma
- Eli Lilly
- Glaxo Smith Kline
- Lundbeck
- Novartis
- OmniPharma
- Pfizer
- Phenicia
- Servier
- UPO
- National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES) [4280]
- National Council on Science and Technology (CONACyT) [G30544-H]
- New Zealand Ministry of Health, Alcohol Advisory Council
- Health Research Council
- WHO (Geneva)
- WHO (Nigeria)
- Federal Ministry of Health, Abuja, Nigeria
- Health & Social Care Research & Development Division of the Public Health Agency
- National Institute of Health of the Ministry of Health of Peru
- project Epidemiology of Mental Health [PL 0256]
- European Economic Area Financial Mechanism
- Norwegian Financial Mechanism
- Polish Ministry of Health
- Champalimaud Foundation
- Gulbenkian Foundation
- Foundation for Science and Technology (FCT)
- Ministry of Public Health
- Eli Lilly Romania SRL
- US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
- National Institute of Drug Abuse
- South African Department of Health
- University of Michigan
- Shenzhen Bureau of Health
- Shenzhen Bureau of Science, Technology, and Information
- Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
- Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
- National Institute of Mental Health (NIMH) [U01-MH60220]
- National Institute of Drug Abuse (NIDA)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Robert Wood Johnson Foundation (RWJF) [044708]
- John W. Alden Trust
- Medical Research Council of South Africa (MRC)
Ask authors/readers for more resources
The study aimed to investigate the impact of prior mental disorders on depression outcomes in individuals with 12-month MDD. Findings showed that individuals with non-depressive distress, fear, and externalising disorders prior to MDD diagnosis were more likely to experience higher impairment and suicidality. These results highlight the importance of assessing psychiatric history, particularly regarding anxiety and externalising disorders, in individuals with MDD.
Aims Major depressive disorder (MDD) is characterised by a recurrent course and high comorbidity rates. A lifespan perspective may therefore provide important information regarding health outcomes. The aim of the present study is to examine mental disorders that preceded 12-month MDD diagnosis and the impact of these disorders on depression outcomes. Methods Data came from 29 cross-sectional community epidemiological surveys of adults in 27 countries (n = 80 190). The Composite International Diagnostic Interview (CIDI) was used to assess 12-month MDD and lifetime DSM-IV disorders with onset prior to the respondent's age at interview. Disorders were grouped into depressive distress disorders, non-depressive distress disorders, fear disorders and externalising disorders. Depression outcomes included 12-month suicidality, days out of role and impairment in role functioning. Results Among respondents with 12-month MDD, 94.9% (s.e. = 0.4) had at least one prior disorder (including previous MDD), and 64.6% (s.e. = 0.9) had at least one prior, non-MDD disorder. Previous non-depressive distress, fear and externalising disorders, but not depressive distress disorders, predicted higher impairment (OR = 1.4-1.6) and suicidality (OR = 1.5-2.5), after adjustment for sociodemographic variables. Further adjustment for MDD characteristics weakened, but did not eliminate, these associations. Associations were largely driven by current comorbidities, but both remitted and current externalising disorders predicted suicidality among respondents with 12-month MDD. Conclusions These results illustrate the importance of careful psychiatric history taking regarding current anxiety disorders and lifetime externalising disorders in individuals with MDD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available